Removal of serine proteases by treatment with finely divided silicon dioxide
View Patent ↗The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
1. A method for preparing an Immunoglobulin G (IgG) composition having a reduced amount of a serine protease or a serine protease zymogen, the method comprising the steps of:
(a) precipitating a cryo-poor plasma fraction, in a first precipitation step, with from about 6% to about 10% alcohol at a pH of from about 7.0 to 7.5 to obtain a first precipitate and a first supernatant;
(b) precipitating IgG from the first supernatant, in a second precipitation step, with from about 23% to about 27% alcohol at a pH of from about 6.7 to about 7.3 to form a second precipitate;
(c) re-suspending the second precipitate to form a suspension;
(d) contacting the suspension with finely divided silicon dioxide (SiO 2 ) under a solution condition suitable to bind a serine protease or serine protease zymogen; and
(e) separating the SiO 2 from the suspension to form a clarified suspension.
2. The method of claim 1 , wherein step (b) comprises adjusting the ethanol concentration of the first supernatant formed in step (a) to about 25% (v/v) at a temperature from about −7° C. to about −9° C.
3. The method of claim 2 , wherein step (d) comprises the addition SiO 2 to a final concentration of from about 0.02 grams per gram precipitate formed in step (b) to about 0.06 grams per gram precipitate formed in step (b).
4. The method of claim 1 , wherein the solution condition suitable to bind a serine protease or serine protease zymogen comprises a pH from 4.5 to 6.0 and a conductivity of from 0.1 mS/cm to 3 mS/cm.
5. The method of claim 4 , wherein the pH of the solution condition suitable to bind a serine protease or serine protease zymogen is from 4.9 to 5.3.
6. The method of claim 4 , wherein the conductivity of the solution condition suitable to bind a serine protease or serine protease zymogen is from 0.5 mS/cm to 2 mS/cm.
7. The method of claim 1 , wherein step (c) comprises re-suspending the second precipitate formed in step (b) with a re-suspension buffer containing phosphate and acetate, wherein the pH of the buffer is adjusted with from 300 mL to 700 mL of glacial acetic acid per 1000 L of re-suspension buffer.
8. The method of claim 5 , wherein the conductivity of the solution condition suitable to bind a serine protease or serine protease zymogen is from about 0.5 mS/cm to about 2 mS/cm.
9. The method of claim 1 , wherein step (e) comprises the sub-steps of:
(i) separating the SiO 2 from the suspension by filtering the suspension through a filter press to form a clarified suspension;
(ii) washing the filter press with at least 3 filter press dead volumes of a wash buffer having a pH of from about 4.6 to about 5.3, thereby forming a wash solution; and
(iii) combining the clarified suspension formed in sub-step (i) with the wash solution formed in sub-step (ii), thereby forming an enriched IgG composition.
10. The method of claim 1 , wherein the method further comprises the steps of:
(f) precipitating IgG from the clarified suspension formed in step (e), in a third precipitation step, with a final alcohol concentration of from about 22% to about 28% alcohol at a pH of from about 6.7 to about 7.3 to form a third precipitate;
(g) re-suspending the third precipitate to form a second suspension; and
(h) separating the soluble fraction from the second suspension formed in step (e), thereby forming an enriched IgG composition.
11. The method of claim 1 , wherein the method further comprises an anion exchange chromatography enrichment step.
12. The method of claim 1 , wherein the method further comprises a cation exchange chromatography enrichment step.
13. The method of claim 1 , wherein the method further comprises at least one viral inactivation or removal step.
14. The method of claim 1 , wherein the alcohol concentration in the first precipitation step (a) is achieved by the spray addition of alcohol into the cryo-poor plasma fraction.
15. The method of claim 1 , wherein the alcohol concentration in the second precipitation step (b) is achieved by the spray addition of alcohol into the first supernatant.
16. The method of claim 10 , wherein the alcohol concentration in the third precipitation step (f) is achieved by the spray addition of alcohol into the clarified suspension.
17. The method of claim 1 , wherein the pH of the first precipitation step (a) is maintained throughout the first precipitation step by continuous monitoring and adjustment of the pH.
18. The method of claim 1 , wherein the pH of the second precipitation step (b) is maintained throughout the second precipitation step by continuous monitoring and adjustment of the pH.
19. The method of claim 10 , wherein the pH of the third precipitation step (f) is maintained throughout the third precipitation step by continuous monitoring and adjustment of the pH.
20. The method of claim 1 , wherein step (b) comprises adjusting the ethanol concentration of the first supernatant formed in step (a) to from about 24% to about 26%.
21. The method of claim 1 , wherein step (b) is performed at a temperature from about −7° C. to about −9° C.